

# Darren R Veach

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6320208/publications.pdf>

Version: 2024-02-01

55  
papers

4,551  
citations

201385

27  
h-index

155451

55  
g-index

59  
all docs

59  
docs citations

59  
times ranked

6021  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 125-137.	1.9	5
2	A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 532-541.	3.2	19
3	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. <i>Clinical Cancer Research</i> , 2021, 27, 2050-2060.	3.2	13
4	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. <i>Bioconjugate Chemistry</i> , 2021, 32, 649-654.	1.8	6
5	An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy. <i>Bioconjugate Chemistry</i> , 2020, 31, 501-506.	1.8	16
6	Alpha radioimmunotherapy using <sup>225</sup> Ac-proteus-DOTA for solid tumors - safety at curative doses. <i>Theranostics</i> , 2020, 10, 11359-11375.	4.6	26
7	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted $\alpha$ -particle therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15172-15181.	3.3	16
8	First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1580-1587.	2.8	5
9	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 881-891.	3.2	21
10	ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts. <i>Molecular Pharmaceutics</i> , 2018, 15, 2133-2141.	2.3	4
11	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. <i>Nature Communications</i> , 2018, 9, 1629.	5.8	37
12	Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 217.	3.4	93
13	Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8448-E8457.	3.3	34
14	<i>In vivo</i> immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). <i>Oncotarget</i> , 2017, 8, 65917-65931.	0.8	17
15	Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. <i>Science Translational Medicine</i> , 2016, 8, 367ra167.	5.8	23
16	Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor Axis Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 73S-78S.	2.8	16
17	Remodeling the Vascular Microenvironment of Glioblastoma with $\alpha$ -Particles. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1771-1777.	2.8	25
18	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. <i>EJNMMI Research</i> , 2016, 6, 7.	1.1	32

#	ARTICLE	IF	CITATIONS
19	Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2014, 20, 2350-2362.	3.2	44
20	Imatinib resistance and microcytic erythrocytosis in a Kit <sup>V558I</sup> ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2276-83.	3.3	26
21	Fluorine-labeled Dasatinib Nanoformulations as Targeted Molecular Imaging Probes in a PDGFB-driven Murine Glioblastoma Model. <i>Neoplasia</i> , 2012, 14, 1132-IN8.	2.3	37
22	Dosimetry of 18F-Labeled Tyrosine Kinase Inhibitor SKI-249380, a Dasatinib-Tracer for PET Imaging. <i>Molecular Imaging and Biology</i> , 2012, 14, 25-31.	1.3	10
23	A magnetic bead-based protein kinase assay with dual detection techniques. <i>Analytical Biochemistry</i> , 2011, 408, 5-11.	1.1	16
24	<sup>124</sup> I-Iodopyridopyrimidinone for PET of Abl Kinase-Expressing Tumors In Vivo. <i>Journal of Nuclear Medicine</i> , 2010, 51, 121-129.	2.8	9
25	Cell Treatment and Lysis in 96-Well Filter-Bottom Plates for Screening Bcr-Abl Activity and Inhibition in Whole-Cell Extracts. <i>Journal of Biomolecular Screening</i> , 2010, 15, 434-440.	2.6	4
26	Imatinib Upregulates Compensatory Integrin Signaling in a Mouse Model of Gastrointestinal Stromal Tumor and Is More Effective When Combined with Dasatinib. <i>Molecular Cancer Research</i> , 2010, 8, 1271-1283.	1.5	34
27	Abstract LB-299: F-dasatinib inhibits glioma cell proliferation and alters expression of PDGFR signaling pathway intermediates in PDGFR-overexpressing glioma models. , 2010, , .		0
28	Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring <i>KIT</i> AY502-3ins Mutation: An <i>In vitro</i> Mutagenesis Screen for Drug Resistance. <i>Clinical Cancer Research</i> , 2009, 15, 6862-6870.	3.2	86
29	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: Toward selective Abl inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6872-6876.	1.0	12
30	A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates. <i>Analytical Biochemistry</i> , 2008, 375, 18-26.	1.1	20
31	Sorafenib Inhibits the Imatinib-Resistant <i>KIT</i> T670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2007, 13, 4874-4881.	3.2	144
32	L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. <i>International Journal of Cancer</i> , 2007, 121, 257-264.	2.3	236
33	Synthesis and Biological Evaluation of a Fluorine-18 Derivative of Dasatinib. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5853-5857.	2.9	38
34	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. <i>Journal of Clinical Investigation</i> , 2007, 117, 3846-3856.	3.9	574
35	Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. <i>Proteomics</i> , 2006, 6, 4554-4564.	1.3	48
36	Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7444-7449.	3.3	121

#	ARTICLE	IF	CITATIONS
37	Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9244-9249.	3.3	104
38	A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood, 2005, 105, 1652-1659.	0.6	85
39	PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood, 2005, 105, 3995-4003.	0.6	66
40	DNA photocleavage and biological activity of a pyrene dihydrodioxin. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2173-2176.	1.0	11
41	Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Medicine, 2005, 11, 731-739.	15.2	207
42	Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nuclear Medicine and Biology, 2005, 32, 313-321.	0.3	14
43	BCR-ABL Kinase Dynamics and Drug Resistance.. Blood, 2005, 106, 1996-1996.	0.6	1
44	Enteropathogenic Escherichia coli Use Redundant Tyrosine Kinases to Form Actin Pedestals. Molecular Biology of the Cell, 2004, 15, 3520-3529.	0.9	106
45	Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Nature Genetics, 2004, 36, 906-912.	9.4	74
46	Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia, 2004, 18, 1352-1356.	3.3	35
47	A Cell-Based Screening Method for Resistance of Bcr-Abl Positive Leukemia Identifies the Mutation Pattern for an Alternative Abl Kinase Inhibitor.. Blood, 2004, 104, 558-558.	0.6	6
48	Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase. Cell, 2003, 112, 859-871.	13.5	762
49	Gleevec inhibits A $\beta$ amyloid production but not Notch cleavage. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12444-12449.	3.3	183
50	Two Distinct Phosphorylation Pathways Have Additive Effects on Abl Family Kinase Activation. Molecular and Cellular Biology, 2003, 23, 3884-3896.	1.1	129
51	Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Research, 2003, 63, 6395-404.	0.4	54
52	A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra. Molecular Cancer Therapeutics, 2003, 2, 933-9.	1.9	3
53	Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Research, 2002, 62, 4236-43.	0.4	684
54	Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Research, 2002, 62, 4244-55.	0.4	131

#	ARTICLE	IF	CITATIONS
55	Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 3091-3094.	1.0	28